Risk of venous thromboembolism with bevacizumab in cancer patients

JAMA

Volumn 301, Issue 14, 2009, Pages 1435-

  Kilickap, Saadettin ^a   Arslan, Cagatay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FLUOROURACIL DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; CYTOKINE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; HUMAN; KIDNEY CARCINOMA; LETTER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; CENTRAL VENOUS CATHETERIZATION; NOTE; RISK; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; KIDNEY CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERIZATION, CENTRAL VENOUS; FLUOROURACIL; HUMANS; NEOPLASMS; RISK; VENOUS THROMBOEMBOLISM;

EID: 65349156896     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.444     Document Type: Letter

References (5)

1. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285.
2. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4(9):1405-1417.
3. Yoshikawa R, Yanagi H, Noda M, et al. Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. Oncol Rep. 2005;13(4):627-632.
4. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil: an electron microscopic study of late effects in rabbits. Scanning Microsc. 1996;10 (3):805-819.
5. Cunningham MJ, Collins MB, Kredentser DC, Malfetano JH. Peripheral infusion ports for central venous access in patients with gynecologic malignancies. Gynecol Oncol. 1996;60(3):397-399.